Phase III trial shows new treatment boosts cure rate for most common form of breast cancer (Nivolumab doubles cure rate)Medical Xpress / Peter MacCallum Cancer Centre / Nature Medicine ^ | Jan. 28, 2025 | Sherene Loi et alPosted on by ConservativeMindA clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
The Phase III CheckMate-7FL trial involved 510 people with the "ER+/HER2-"sub-type which accounts for around 70% of all breast cancers.
ER+/HER2− breast cancer accounts for 70% of the around 2.3 million cases of breast cancer diagnosed worldwide in 2020.
Using chemo to shrink and adding nivolumab (a monoclonal antibody) before having surgery reduced the tumor and doubled the cure rate from standard practice.
To: ConservativeMindAt my church book club I heard about a friend who was at the end of life with breast cancer.